Swiss drugmaker Roche said it plans to invest $50 billion in the U.S. over the next five years, creating more than 12,000 jobs.<\/p>\n
The move makes Roche the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.<\/p>\n
Apple, TSMC, and Swiss drugmaker Novartis have also announced plans to expand in the U.S. in recent months.<\/p>\n
Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.<\/p>\n
The company said it would invest the $50 billion in the U.S. over the next five years, creating more than 12,000 jobs. Roche said 1,000 of the jobs would be with the company, and the rest \u201cin support of new US manufacturing capabilities.\u201d It said it already employs more than 25,000 people in 24 sites across eight states in the U.S.<\/p>\n
Other companies that have announced plans in recent months to increase their U.S. presence as Trump implements tariffs\u00a0include Apple (AAPL), which said it would spend $500 billion<\/a> in the U.S. over the next four years, and chipmaking giant Taiwan Semiconductor Manufacturing Company (TSM), which is planning a\u00a0$100 billion<\/a> outlay in U.S.-based manufacturing facilities. The prospect of\u00a0 pharma<\/a> tariffs are also weighing on Roche and Novartis (NVS), which this month announced plans to invest $23 billion<\/a> in the U.S.<\/p>\n